Seelos therapeutics announces dosing of the first patients in a study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major depressive disorder

New york, jan. 15, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patients in its registrational...
SEEL Ratings Summary
SEEL Quant Ranking